Predictors of Inadequate Serum Urate Response to Low-Dose Febuxostat in Male Patients with Gout

References

• Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheumatic Dis. 2017;76(1):29–42. doi:10.1136/annrheumdis-2016-209707
   PubMed Web of Science ®Google Scholar
• FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res. 2020;72(6):744–760.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Dalbeth N. Critical appraisal of serum urate targets in the management of gout. Nat Rev Rheumatol. 2022;18(10):603–609. doi:10.1038/s41584-022-00816-1
   PubMed Web of Science ®Google Scholar
• Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522–1528.
   PubMed Web of Science ®Google Scholar
• Doherty M, Jenkins W, Richardson H, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018;392(10156):1403–1412.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461.
   PubMed Web of Science ®Google Scholar
• Ye P, Yang S, Zhang W, et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther. 2013;35(2):180–189. doi:10.1016/j.clinthera.2012.12.011
   PubMed Web of Science ®Google Scholar
• Sheer R, Null KD, Szymanski KA, et al. Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. Clinicoecon Outcomes Res. 2017;9:629–639. doi:10.2147/CEOR.S139939
   PubMed Web of Science ®Google Scholar
• Graham GG, Stocker SL, Kannangara DRW, et al. Predicting response or non-response to urate-lowering therapy in patients with gout. Curr Rheumatol Rep. 2018;20(8):47. doi:10.1007/s11926-018-0760-2
   PubMed Web of Science ®Google Scholar
• Becker MA, MacDonald PA, Hunt BJ, et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleo Nucle Nuc Acid. 2008;27(6):585–591.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tamaki S, Ide Y, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018;77(2):270–276. doi:10.1136/annrheumdis-2017-211574
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Stamp LK. Gout: why compare the effectiveness of suboptimal gout management? Nat Rev Rheumatol. 2015;11(9):506–507. doi:10.1038/nrrheum.2015.94
   PubMed Web of Science ®Google Scholar
• Kamatani N, Fujimori S, Hada T, et al. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: Phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S13–S18. doi:10.1097/RHU.0b013e31821d36cc
   PubMed Web of Science ®Google Scholar
• Liang N, Sun M, Sun R, et al. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. Arthritis Res Ther. 2019;21(1):200.
   PubMed Web of Science ®Google Scholar
• Yan F, Xue X, Lu J, et al. Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion. Arthritis Rheumatol. 2022;74(12):2015–2023.
   PubMed Web of Science ®Google Scholar
• Bando Y, Toyama H, Kanehara H, et al. Chronic hyperglycemia may attenuate the serum-uric-acid-lowering effect of low-dose febuxostat in Japanese patients with type 2 diabetes mellitus. Diabetol Int. 2016;7(3):1.
   PubMedGoogle Scholar
• Ichiro Hisatome KI, Mineo I. Japanese society of gout and uric & nucleic acids 2019 guidelines for management of hyperuricemia and Gout 3rd edition. Gout and Uric Nucleic Acids. 2020;44:1.
   Google Scholar
• Singh JA, Akhras KS, Shiozawa A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther. 2015;17(1):120.
   PubMedGoogle Scholar
• Hu S, Sun M, Li M, et al. Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study. Rheumatology. 2022.
   Web of Science ®Google Scholar
• Scheepers L, van Onna M, Stehouwer CDA, et al. Medication adherence among patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;47(5):689–702. doi:10.1016/j.semarthrit.2017.09.007
   PubMed Web of Science ®Google Scholar
• Qaseem A, Harris RP, Forciea MA, et al. Management of acute and recurrent gout: a clinical practice guideline from the American college of physicians. Ann Intern Med. 2017;166(1):58–68.
   PubMed Web of Science ®Google Scholar
• Abhishek A, Doherty M. Education and non-pharmacological approaches for gout. Rheumatology. 2018;57(suppl_1):i51–i58.
   PubMedGoogle Scholar
• Hatoum H, Khanna D, Lin SJ, et al. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Postgrad Med. 2014;126(2):65–75. doi:10.3810/pgm.2014.03.2741
   PubMed Web of Science ®Google Scholar
• Kang EH. Considerations for choosing first-line urate-lowering treatment in older patients with comorbid conditions. Drugs Aging. 2022;39(12):923–933. doi:10.1007/s40266-022-00986-3
   PubMed Web of Science ®Google Scholar
• Stamp LK, Chapman PT, Barclay M, et al. Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial. Rheumatology. 2018;57(12):2183–2189. doi:10.1093/rheumatology/key237
   PubMed Web of Science ®Google Scholar
• Graham GG, Kannangara DR, Stocker SL, et al. Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Br J Clin Pharmacol. 2013;76(6):932–938.
   PubMed Web of Science ®Google Scholar
• Heikal MM, Shaaban AA, Elkashef WF, et al. Effect of febuxostat on biochemical parameters of hyperlipidemia induced by a high-fat diet in rabbits. Can J Physiol Pharmacol. 2019;97(7):611–622. doi:10.1139/cjpp-2018-0731
   PubMed Web of Science ®Google Scholar
• Guma M, Dadpey B, Coras R, et al. Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes. Arthritis Res Ther. 2022;24(1):175. doi:10.1186/s13075-022-02852-4
   PubMed Web of Science ®Google Scholar
• Duquesne J, Bouget V, Cournede PH, et al. Machine learning identifies a profile of inadequate responder to methotrexate in rheumatoid arthritis. Rheumatology. 2022.
   Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American college of rheumatology guidelines for management of gout. part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1.
   Web of Science ®Google Scholar
• Qi H, Sun M, Terkeltaub R, et al. Response to febuxostat according to clinical subtypes of hyperuricemia: a prospective cohort study in primary gout. Arthritis Res Ther. 2023;25(1):241.
   PubMed Web of Science ®Google Scholar
• Miyata H, Takada T, Toyoda Y, et al. Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations. Front Pharmacol. 2016;7(518). doi:10.3389/fphar.2016.00518.
   PubMedGoogle Scholar
• Stamp LK, Topless R, Miner JN, et al. No association between ATP-binding cassette transporter G2 rs2231142 (Q141K) and urate-lowering response to febuxostat. Rheumatology. 2019;58(3):547–548.
   PubMed Web of Science ®Google Scholar
• Mukoyoshi M, Nishimura S, Hoshide S, et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 2008;38(5):496–510. doi:10.1080/00498250801956350
   PubMed Web of Science ®Google Scholar